Fluvastatin in the therapy of acute coronary syndrome: Rationale and design of a multicenter, randomized, double-blind, placebo-controlled trial (The FACS Trial)[ISRCTN81331696] by Ostadal, Petr et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
Current Controlled Trials in 
Cardiovascular Medicine
Open Access Research
Fluvastatin in the therapy of acute coronary syndrome: Rationale 
and design of a multicenter, randomized, double-blind, 
placebo-controlled trial (The FACS Trial)[ISRCTN81331696]
Petr Ostadal*1, David Alan1, Petr Hajek1, Jiri Vejvoda1, Martin Mates1, 
Peter Blasko1, Josef Veselka1, Milan Kvapil2, Jiri Kettner3, Martin Wiendl3, 
Ondrej Aschermann4, Josef Slaby5, Eduard Nemecek6, Frantisek Holm7, 
Marek Rac8, Milan Macek9 and Jana Cepova10
Address: 1Department of Cardiology, University Hospital Motol and Charles University, 2nd Faculty of Medicine, Prague, Czech Republic, 
2Department of Internal Medicine, University Hospital Motol and Charles University, 2nd Faculty of Medicine, Prague, Czech Republic, 
3Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 4Department of Cardiology, Na Homolce 
Hospital, Prague, Czech Republic, 5Department of Medicine, Hospital Kolin, Kolin, Czech Republic, 61st Department of Medicine, Hospital Na 
Frantisku, Prague, Czech Republic, 7Department of Cardiology, Regional Hospital Liberec, Liberec, Czech Republic, 8Internal Medicine & Clinical 
Pharmacology Department, Faculty Hospital Nitra, Nitra, Slovakia, 9Institute of Biology and Medical Genetics, University Hospital Motol and 
Charles University, 2nd Faculty of Medicine, Prague, Czech Republic and 10Department of Clinical Biochemistry and Pathobiochemistry, 
University Hospital Motol and Charles University, 2nd Faculty of Medicine, Prague, Czech Republic
Email: Petr Ostadal* - ostadal@yahoo.com; David Alan - david.alan@seznam.cz; Petr Hajek - petr_hajek@hotmail.com; 
Jiri Vejvoda - jirkavejvoda@seznam.cz; Martin Mates - mates@bon.cz; Peter Blasko - blaskopeter@hotmail.com; 
Josef Veselka - veselka.josef@seznam.cz; Milan Kvapil - milan.kvapil@lfmotol.cuni.cz; Jiri Kettner - jiri.kettner@medicon.cz; 
Martin Wiendl - mawi@medicon.cz; Ondrej Aschermann - ondrej.aschermann@homolka.cz; Josef Slaby - slaby.josef@post.cz; 
Eduard Nemecek - eduardn@email.cz; Frantisek Holm - frantisek.holm@nemlib.cz; Marek Rac - marekrac@orangemail.sk; 
Milan Macek - milan.macek@lfmotol.cuni.cz; Jana Cepova - Janacepova@seznam.cz
* Corresponding author    
statinfluvastatinacute coronary syndromeC-reactive proteininterleukin 6pregnancy-associated plasma protein A
Abstract
Background:  Activation of inflammatory pathways plays an important contributory role in
coronary plaque instability and subsequent rupture, which can lead to the development of acute
coronary syndrome (ACS). Elevated levels of serum inflammatory markers such as C-reactive
protein (CRP) represent independent risk factors for further cardiovascular events. Recent
evidence indicates that in addition to lowering cholesterol levels, statins also decrease levels of
inflammatory markers. Previous controlled clinical trials reporting the positive effects of statins in
participants with ACS were designed for very early secondary prevention. To our knowledge, no
controlled trials have evaluated the potential benefits of statin therapy, beginning immediately at
the time of hospital admission. A previous pilot study performed by our group focused on early
initiation of cerivastatin therapy. We demonstrated a highly significant reduction in levels of
inflammatory markers (CRP and interleukin-6). Based on these preliminary findings, we are
conducting a clinical trial to evaluate the efficacy of another statin, fluvastatin, as an early
intervention in patients with ACS.
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Methods:  The FACS-trial (Fluvastatin in the therapy of Acute Coronary Syndrome) is a
multicenter, randomized, double-blind, placebo-controlled study evaluating the effects of fluvastatin
therapy initiated at the time of hospital admission. The study will enroll 1,000 participants admitted
to hospital for ACS (both with and without ST elevation). The primary endpoint for the study is
the influence of fluvastatin therapy on levels of inflammatory markers (CRP and interleukin-6) and
on pregnancy associated plasma protein A (PAPP-A). A combined secondary endpoint is 30-day and
one-year occurrence of death, nonfatal myocardial infarction, recurrent symptomatic ischemia,
urgent revascularization, and cardiac arrest.
Conclusion: The primary objective of the FACS trial is to demonstrate that statin therapy, when
started immediately after hospital admission for ACS, results in reduction of inflammation and
improvement of prognosis. This study may contribute to new knowledge regarding therapeutic
strategies for patients suffering from ACS and may offer additional clinical indications for the use
of statins.
Background
During the past decade, inflammation has often been
cited as a major factor in the pathogenesis of atherosclero-
sis and its clinical sequelae, including ischemic heart dis-
ease. It was found that traditional risk factors such as
hypertension, hypercholesterolemia, diabetes, and smok-
ing could not fully account for the development of coro-
nary stenosis in all patients suffering from ischemic heart
disease. Intensive study of the pathogenesis of coronary
plaque development and rupture led to the hypothesis
that inflammatory factors contribute to this process. For
example, T-lymphocytes and monocytes/macrophages
have been repeatedly identified in plaque lesions; ele-
vated levels of acute phase proteins (C-reactive protein,
serum amyloid A, fibrinogen), cytokines (interleukin 1,
interleukin 6, interleukin 8, tumor necrosis factor), and
adhesive molecules (ICAM-1) correlate with the worse
prognoses in patients with ischemic heart disease [1-5].
Furthermore, the increased level of C-reactive protein
(CRP) is now widely recognized as being an independent
risk factor for a higher incidence of non-fatal and fatal cor-
onary events in patients with chronic ischemic heart dis-
ease and acute coronary syndromes [6-9].
Activation of the immune reaction in acute ischemic heart
disease likely derives from: (i) pathological events occur-
ring in the arterial wall where the lesion develops, leading
to plaque rupture and the subsequent clinical conse-
quences and (ii) myocardial necrosis, which triggers proc-
esses involved in removal of the necrotic mass and
replacement with scar tissue. Whereas activation of plaque
inflammation (as noted above) serves as a marker for
plaque instability, elevation of inflammatory factors from
the second source correlates with the extent of myocardial
necrosis.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, lower cholesterol levels by
decreasing the production of low-density lipoproteins
(LDL) and up-regulating the expression of the LDL-recep-
tor. These drugs are widely used in patients with hyperc-
holesterolemia for primary and secondary prevention of
coronary artery disease because of their efficacy in reduc-
ing cardiovascular morbidity and mortality [10-12]. Sur-
prisingly, statin therapy also improves prognosis in
patients with normal or low cholesterol levels[13]. Evalu-
ation of the non-lipid effects of statins reveals a possible
beneficial effect mediated by the reduction of inflamma-
tory markers, namely, CRP. This effect seems to be inde-
pendent of cholesterol level [1,14]. The mechanisms by
which statins inhibit inflammation are not fully under-
stood. It has been reported that they suppress production
of monocyte chemotactic protein-1 (MCP-1) [15], as well
as matrix metalloproteinases (MMPs) [5,16,17]. Statins
also decrease macrophage expression of soluble ICAM-1
and secretion of IL-1, IL-6, TNF-alpha [5,18-23].
A number of large clinical trials have been designed to
investigate the effect of statins in treating acute coronary
syndromes (ACS) [24-30] Because patients in these stud-
ies were randomized later after being admitted to hospi-
tal, often after they had been clinically stabilized, these
randomized, double blind trials focused more on early
secondary prevention, as opposed to evaluating earlier
therapy to target plaque instability in ACS. Furthermore,
broad exclusion criteria in some of these trials, including
coronary intervention during the index hospitalization
visit, deter from the generalizability of their results to the
majority of patients treated according to current clinical
practice [24]. Nevertheless, these studies have shown
promising results, despite the fact that the statins were
administered after activation of the immune mechanisms
was completed and after the inflammatory reaction was
already fully developed.
Little information is available on the efficacy of statins in
treating ACS at an earlier phase, i.e., at the time of hospital
admission. Recently published data from experimentalCurrent Controlled Trials in Cardiovascular Medicine 2005, 6:4 http://cvm.controlled-trials.com/content/6/1/4
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projects [31-35] and from small clinical trials [36-38])
have shown a positive effect of statins when they are
administered in the acute phase of ACS. Our preliminary
results with cerivastatin treatment in patients with non-ST
segment elevation ACS starting at the time of hospital
admission have shown the safety of such a strategy as well
as a decrease in inflammatory markers (CRP, IL-6) by 24-
hour follow-up, as compared to the non-treated group
[39]. Based on these pilot data, we are conducting a clini-
cal trial to evaluate fluvastatin therapy administered to




The objectives of the FACS trial are to determine:
(i) Whether initiation of fluvastatin therapy in patients
with ACS immediately after hospital admission decreases
levels of CRP, IL-6, and pregnancy-associated plasma pro-
tein A/ proform eosinophilic major basic protein (PAPP-
A/proMBP), which represent indirect markers of plaque
instability and indicators of poor prognosis; and
(ii) Whether initiation of fluvastatin therapy decreases the
occurrence of ischemic events (death, nonfatal myocar-
dial infarction, recurrent symptomatic ischemia, urgent
revascularization, cardiac arrest) in patients with ACS.
Overview
This is a prospective, 30-day, multicenter, randomized,
double-blind, placebo-controlled study in 1,000 patients
with ACS. Patients are enrolled from 10 sites in the Czech
Republic and Slovakia. At each institution, the protocol
and the informed consent form are reviewed and
approved by the institutional ethics committee before
study initiation. Eligible patients are randomized to one
of two treatment groups immediately after hospital
Design of the FACS trial in comparison to other trials evaluating statins in ACS patients Figure 1
Design of the FACS trial in comparison to other trials evaluating statins in ACS patients. In the Pravastatin in Acute Coronary 
Treatment (PACT) trial statin, therapy was initiated within 24 hours of onset of ACS. In the Myocardial Ischemia Reduction 
With Aggressive Cholesterol Lowering (MIRACL) trial, patients were randomized 24 to 96 hours after ACS. In the Z-phase of 
the A-to-Z trial, simvastatin therapy was initiated within 5 days of the onset of ACS, after clinical stabilization. In the Pravastatin 
or Atorvastatin Evaluation and Infection Therapy (PROVE IT) trial, patients were randomized up to 10 days after ACS. In the 
Lipid-Coronary Artery Disease (L-CAD) trial, statin therapy was initiated up to ten days following the onset of ACS. In the Flu-
vastatin on Risk Diminishing After Acute Myocardial Infarction (FLORIDA) trial, patients were randomized up to two weeks 
after ACS.
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admission (within one hour). One group is assigned 80
mg/day fluvastatin (Lescol XL), with the other group
receiving placebo. Participants are followed on an inten-
tion-to-treat basis. The primary endpoint relates to levels
of CRP, IL-6, and PAPP-A/proMBP. The secondary end-
point is the occurrence of an ischemic event, defined as
death, nonfatal myocardial infarction (MI), recurrent
symptomatic myocardial ischemia, cardiac arrest with
resuscitation, and urgent revascularization.
Study population
This study will enroll high-risk patients admitted to the
hospital for ACS. Eligible patients with ST elevation ACS
must have resting chest pain less than 12 hours before
admission and either ≥  1 mm ST-segment elevation in 2
or more continuous leads or new left bundle branch block
on ECG. Those with non-ST elevation ACS must have rest-
ing chest pain during the previous 48 hours and either ≥  1
mm ST segment depression or negative T waves in 2 or
more continuous leads.
Exclusion criteria
Subjects are excluded from study participation if they are
<18 years of age or if they have concomitant active liver
disease or persistent elevation of transaminases (> 3 times
the upper limit of normal), a history of lipid-lowering
therapy less than 30 days before the index event or a
known allergy to fluvastatin or to any additives present in
the drug. Other exclusions include inability to ingest oral
medication, unwillingness to be followed for the duration
of the study, muscle disease (e.g., myositis), and creatine
kinase ≥  5 times the upper limit of normal due to condi-
tions other than myocardial infarction. Women of child-
bearing potential who are pregnant, nursing or who are
not using effective contraception will also be excluded.
Follow-up
After obtaining informed consent, blood samples are
taken from patients for examination of inflammatory
markers (CRP, IL-6, and PAPP-A/proMBP). Patients are
then randomized to 80 mg fluvastatin (Lescol XL) or to
placebo immediately p.o. Medical history and physical
examination, standard 12-lead ECG, blood lipid profile,
and liver function tests are performed as part of partici-
pants' routine admission care. Fluvastatin 80 mg or pla-
cebo are then taken once daily for 30 days. Follow-up
measurement of inflammatory markers (CRP, IL-6, and
PAPP-A/proMBP) is performed on day 2 and day 30. Fol-
low-up visits are scheduled at pre-discharge, day 30, 90,
180 and 360. Blood liver function and creatine kinase
tests are done at pre-discharge and at the 30-day visits. At
day 30, the lipid profile is also examined, and study med-
ication is withdrawn. All visits include assessment of
ischemic events and recent medical history since the last
follow-up visit, including use of concomitant medications
(Figure 2).
During follow-up, no specific recommendations are made
with respect to diagnostic and therapeutic strategy, except
that other lipid-lowering drugs should not be given after
randomization until day 30. All management decisions
Study design of the FACS Trial Figure 2
Study design of the FACS Trial. Patients admitted with acute coronary syndrome (ACS) are randomized to either fluvastatin 80 
mg or placebo for 30 days. Patients are then followed for one year. Assessments of CRP, IL-6, and PAPP-A/proMBP (LAB) are 
performed at admission, on day 2, and day 30.
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are left to the discretion of each patient's treating
physician.
Safety
The principal safety concerns are hepatic dysfunction and
myopathy. If a patient's serum transaminase levels are
persistently elevated to > 3 times the upper limit of nor-
mal, the study medication is discontinued. Similarly,
study medication is stopped if the patient develops mus-
cle pain, weakness, or tenderness in association with a
serum creatine kinase level > 10 times the upper limit of
normal.
Sample size
The trial will enroll 1,000 patients, to ensure adequate
power to detect significant treatment benefit of 80 mg flu-
vastatin (Lescol XL) with respect to the primary endpoint
(30-day decrease of CRP and IL-6) and the combined sec-
ondary endpoint (death, nonfatal myocardial infarction,
recurrent symptomatic ischemia, urgent revascularization,
cardiac arrest). With 500 patients randomized to 80 mg
fluvastatin (Lescol XL) and 500 patients randomized to
placebo, the trial will have more than 80 % power to
detect a decrease in CRP level by 1.36 µg/L and a decrease
in IL-6 level by 1.09 ng/L. Calculations are based on a two-
sample  t-test. The estimated combined secondary end-
point rate at 30-days is 20 %. Based on comparison of pro-
portions with p = 0.05 test significance, the trial will have
more than 80 % power to detect a 33% decrease in the
combined secondary endpoint.
Conclusion
The FACS trial is the first multicenter, randomized, dou-
ble-blind, placebo-controlled trial investigating the effects
of fluvastatin therapy started immediately after hospital
admission in patients with ACS.
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